Advertisement admin, Author at Pharmaceutical Business review - Page 406 of 458
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by Lavillcok Lavillcok

Repligen begins Phase 1b study of RG3039

The study will evaluate the safety and plasma pharmacokinetics of multiple doses of RG3039, an orally bioavailable small molecule inhibitor of an RNA processing enzyme called DcpS, in

Boehringer completes Phase III studies of nintedanib

The two identical 52-week, double-blind, randomised, placebo-controlled trials with matching twice-daily 150mg dosing, inclusion criteria and endpoints enrolled a total of 970 patients in 20 countries. The annual